Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Nami TomiyamaYoshihiko TasakiTeruaki SuginoYosuke SugiyamaTaku NaikiToshiki EtaniKazumi TaguchiNayuka MatsuyamaYasuhito SueYoshihisa MimuraKunihiro OdagiriYusuke NodaMaria AokiYoshinobu MoritokiSatoshi NozakiSatoshi KurokawaAtsushi OkadaNoriyasu KawaiYoko Furukawa-HibiTakahiro YasuiPublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
Hemoglobin and neutrophil levels may represent crucial biomarkers for predicting the effectiveness of ipilimumab plus nivolumab therapy in patients with renal cell carcinoma.